Bibbò Stefano, Settanni Carlo Romano, Porcari Serena, Bocchino Enrico, Ianiro Gianluca, Cammarota Giovanni, Gasbarrini Antonio
UOC Medicina Interna e Gastroenterologia, Dipartimento di Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario "A. Gemelli" IRCCS, 00168 Roma, Italy.
Istituto di Patologia Speciale Medica, Università Cattolica del Sacro Cuore, 00168 Roma, Italy.
J Clin Med. 2020 Jun 5;9(6):1757. doi: 10.3390/jcm9061757.
In the past decade, fecal microbiota transplantation (FMT) has rapidly spread worldwide in clinical practice as a highly effective treatment option against recurrent infection. Moreover, new evidence also supports a role for FMT in other conditions, such as inflammatory bowel disease, functional gastrointestinal disorders, or metabolic disorders. Recently, some studies have identified specific microbial characteristics associated with clinical improvement after FMT, in different disorders, paving the way for a microbiota-based precision medicine approach. Moreover, donor screening has become increasingly more complex over years, along with standardization of FMT and the increasing number of stool banks. In this narrative review, we discuss most recent evidence on the screening and selection of the stool donor, with reference to recent studies that have identified specific microbiological features for clinical conditions such as infection, irritable bowel syndrome, inflammatory bowel disease, and metabolic disorders.
在过去十年中，粪便微生物群移植（FMT）作为一种治疗复发性感染的高效疗法，已在全球临床实践中迅速推广。此外，新证据也支持FMT在其他病症中的作用，如炎症性肠病、功能性胃肠疾病或代谢紊乱。最近，一些研究已经确定了在不同病症中，FMT后临床改善所相关的特定微生物特征，为基于微生物群的精准医学方法铺平了道路。此外，多年来，随着FMT的标准化以及粪便库数量的增加，供体筛选变得越来越复杂。在这篇叙述性综述中，我们参考最近的研究，讨论了粪便供体筛选和选择的最新证据，这些研究已经确定了针对感染、肠易激综合征、炎症性肠病和代谢紊乱等临床病症的特定微生物特征。
